Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-TUBB4-001 for TUBB4A-related Leukodystrophy
NCT06369974Phase 2Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of nL-TUBB4-001 in TUBB4A-related leukodystrophy, sponsored by Massachusetts General Hospital. Started Sep 2024; status: enrolling by invitation.
02
Drugs
nL-TUBB4-001
03
Conditions
TUBB4A-related leukodystrophy
Beyond the preview
Go deeper on NCT06369974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369974.